BAY-293 is a Selective KRas-SOS1 Inhibitor for RAS-Driven Tumors Treatment
Members of the RAS family of GTPases (which comprises KRAS, NRAS, and HRAS) are major oncogenes. Especially, mutations in the RAS genes are major oncogenes with a high occurrence rate…